ReviewRespirology (Carlton, Vic.)2013
Adult stem cells for acute lung injury: remaining questions and concerns.
Review in Respirology (Carlton, Vic.), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 42 citations in OpenAlex.
- Advances in natural-product-based nanomaterials for treatment of acute lung injury.Frontiers in bioengineering and biotechnology · 2025Review
- Optimized administration of human embryonic stem cell-derived immunity-and-matrix regulatory cells for mouse lung injury and fibrosis.Stem cell research & therapy · 2024Article
- Role of Extracellular microRNAs in Sepsis-Induced Acute Lung Injury.Journal of immunology research · 2023Review
- Stem cell-based therapy for pulmonary fibrosis.Stem cell research & therapy · 2022Review
- Targeted Therapy for Inflammatory Diseases with Mesenchymal Stem Cells and Their Derived Exosomes: From Basic to Clinics.International journal of nanomedicine · 2022Review
- Host Defense againstJournal of immunology (Baltimore, Md. : 1950) · 2021Article
- Role of miR-466 in mesenchymal stromal cell derived extracellular vesicles treating inoculation pneumonia caused by multidrug-resistant Pseudomonas aeruginosa.Clinical and translational medicine · 2021Article
- Soluble factors of mesenchimal stem cells (FS-MSC) as a potential tool to reduce inflammation in donor's lungs after hypovolemic shock.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2021Article
- Immunity-and-matrix-regulatory cells derived from human embryonic stem cells safely and effectively treat mouse lung injury and fibrosis.Cell research · 2020Article
- Adipose-Derived Mesenchymal Stem Cells AmelioratingFrontiers in cellular and infection microbiology · 2020Article
- Mesenchymal stem cells prevent overwhelming inflammation and reduce infection severity via recruiting CXCR3Clinical & translational immunology · 2020Article
- Therapeutic use of mesenchymal stem cell-derived extracellular vesicles in acute lung injury.Transfusion · 2019Article
- Targeted migration of bone marrow mesenchymal stem cells inhibits silica-induced pulmonary fibrosis in rats.Stem cell research & therapy · 2018Article
- Bone-marrow-derived mesenchymal stem cells inhibit gastric aspiration lung injury and inflammation in rats.Journal of cellular and molecular medicine · 2016Article
- Mesenchymal stem cell therapy for acute respiratory distress syndrome: a light at the end of the tunnel?Anesthesiology · 2015Article
- Cell-based therapy for acute organ injury: preclinical evidence and ongoing clinical trials using mesenchymal stem cells.Anesthesiology · 2014Review
- Influenza causes prolonged disruption of the alveolar-capillary barrier in mice unresponsive to mesenchymal stem cell therapy.American journal of physiology. Lung cellular and molecular physiology · 2014Article
- Year in review 2013: Acute lung injury, interstitial lung diseases, sleep and physiology.Respirology (Carlton, Vic.) · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
Abstract
Acute lung injury (ALI) or acute respiratory distress syndrome remains a major cause of morbidity and mortality in hospitalized patients. The pathophysiology of ALI involves complex interactions between the inciting event, such as pneumonia, sepsis or aspiration, and the host immune response resulting in lung protein permeability, impaired resolution of pulmonary oedema, an intense inflammatory response in the injured alveolus and hypoxemia. In multiple preclinical studies, adult stem cells have been shown to be therapeutic due to both the ability to mitigate injury and inflammation through paracrine mechanisms and perhaps to regenerate tissue by virtue of their multi-potency. These characteristics have stimulated intensive research efforts to explore the possibility of using stem or progenitor cells for the treatment of lung injury. A variety of stem or progenitor cells have been isolated, characterized and tested experimentally in preclinical animal models of ALI. However, questions remain concerning the optimal dose, route and the adult stem or progenitor cell to use. Here, the current mechanisms underlying the therapeutic effect of stem cells in ALI as well as the questions that will arise as clinical trials for ALI are planned are reviewed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.